Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362543553> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4362543553 endingPage "2705" @default.
- W4362543553 startingPage "2705" @default.
- W4362543553 abstract "Abstract Protein therapeutics are often compromised by sub-optimal biodistribution contributing to poor efficacy and adverse events. Drug delivery mechanisms better able to target the disease site and provide localized, sustained drug release have the potential to transform therapeutic standards. PODS crystals (PCs) are natural-mimetic, micron-scale protein co-crystals engineered to incorporate a protein cargo that is sustainably released under the action of resident proteases. PCs are efficiently taken up by phagocytic cells and their cargo protein is subsequently released in a bioactive form. Since blood-circulating phagocytic cells, including monocytes, are actively recruited into the tumor microenvironment, we postulated that monocyte/macrophage-mediated PC delivery could be used as a molecular “Trojan horse” to efficiently deliver therapeutic proteins to target cells. This could improve the pharmacodynamics and pharmacokinetics of protein drug delivery to treat systemic and disseminated diseases. Interleukin-2 (IL-2) is notoriously toxic at the high doses required for therapeutic efficacy. Here, we demonstrate the therapeutic efficacy and tolerability of low doses of PC-IL-2 administered intravenously in a mouse model of melanoma. We further demonstrate the therapeutic benefit of PCs delivering low doses of IL-2, interleukin-15 (IL-15) and interferon-gamma (IFN-γ) in a mouse model of renal cell carcinoma. In all the treated mice, cachexia, a side effect of high-dose cytokine therapy, was notably absent. This study provides proof-of-concept for the utility of intravenously administered PCs to provide a generalised and widely applicable mechanism to effectively deliver protein drugs for the therapy of cancer and other diseases. Citation Format: Michael H. Jones, Nirk E. Quispe Calla, Callum Talbot-Cooper, Hong Zeng, Jonathan Best, Robert Smith. Low-dose crystalline cytokine macrophage mediated Trojan horse immunotherapy of solid cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2705." @default.
- W4362543553 created "2023-04-06" @default.
- W4362543553 creator A5017580715 @default.
- W4362543553 creator A5020333968 @default.
- W4362543553 creator A5034674659 @default.
- W4362543553 creator A5048543838 @default.
- W4362543553 creator A5060588122 @default.
- W4362543553 creator A5061323808 @default.
- W4362543553 date "2023-04-04" @default.
- W4362543553 modified "2023-10-16" @default.
- W4362543553 title "Abstract 2705: Low-dose crystalline cytokine macrophage mediated Trojan horse immunotherapy of solid cancers" @default.
- W4362543553 doi "https://doi.org/10.1158/1538-7445.am2023-2705" @default.
- W4362543553 hasPublicationYear "2023" @default.
- W4362543553 type Work @default.
- W4362543553 citedByCount "0" @default.
- W4362543553 crossrefType "journal-article" @default.
- W4362543553 hasAuthorship W4362543553A5017580715 @default.
- W4362543553 hasAuthorship W4362543553A5020333968 @default.
- W4362543553 hasAuthorship W4362543553A5034674659 @default.
- W4362543553 hasAuthorship W4362543553A5048543838 @default.
- W4362543553 hasAuthorship W4362543553A5060588122 @default.
- W4362543553 hasAuthorship W4362543553A5061323808 @default.
- W4362543553 hasConcept C112705442 @default.
- W4362543553 hasConcept C178790620 @default.
- W4362543553 hasConcept C185592680 @default.
- W4362543553 hasConcept C19831878 @default.
- W4362543553 hasConcept C203014093 @default.
- W4362543553 hasConcept C2777701055 @default.
- W4362543553 hasConcept C2778690821 @default.
- W4362543553 hasConcept C2779820397 @default.
- W4362543553 hasConcept C2780035454 @default.
- W4362543553 hasConcept C502942594 @default.
- W4362543553 hasConcept C71924100 @default.
- W4362543553 hasConcept C8891405 @default.
- W4362543553 hasConcept C98274493 @default.
- W4362543553 hasConceptScore W4362543553C112705442 @default.
- W4362543553 hasConceptScore W4362543553C178790620 @default.
- W4362543553 hasConceptScore W4362543553C185592680 @default.
- W4362543553 hasConceptScore W4362543553C19831878 @default.
- W4362543553 hasConceptScore W4362543553C203014093 @default.
- W4362543553 hasConceptScore W4362543553C2777701055 @default.
- W4362543553 hasConceptScore W4362543553C2778690821 @default.
- W4362543553 hasConceptScore W4362543553C2779820397 @default.
- W4362543553 hasConceptScore W4362543553C2780035454 @default.
- W4362543553 hasConceptScore W4362543553C502942594 @default.
- W4362543553 hasConceptScore W4362543553C71924100 @default.
- W4362543553 hasConceptScore W4362543553C8891405 @default.
- W4362543553 hasConceptScore W4362543553C98274493 @default.
- W4362543553 hasIssue "7_Supplement" @default.
- W4362543553 hasLocation W43625435531 @default.
- W4362543553 hasOpenAccess W4362543553 @default.
- W4362543553 hasPrimaryLocation W43625435531 @default.
- W4362543553 hasRelatedWork W1969876219 @default.
- W4362543553 hasRelatedWork W1978032370 @default.
- W4362543553 hasRelatedWork W1979757582 @default.
- W4362543553 hasRelatedWork W1990964652 @default.
- W4362543553 hasRelatedWork W2049819497 @default.
- W4362543553 hasRelatedWork W2076844872 @default.
- W4362543553 hasRelatedWork W2332367370 @default.
- W4362543553 hasRelatedWork W2400461952 @default.
- W4362543553 hasRelatedWork W4205993769 @default.
- W4362543553 hasRelatedWork W79555446 @default.
- W4362543553 hasVolume "83" @default.
- W4362543553 isParatext "false" @default.
- W4362543553 isRetracted "false" @default.
- W4362543553 workType "article" @default.